Article

Changing Paradigms-Integrating Novel Therapeutics Into the Standard of Care

Author(s):

Prostate cancer affects 1 of every 6 men in the United States

Prostate cancer affects 1 of every 6 men in the United States, but with continuing improvements in strategies and therapeutic agents, death rates have been falling since 1991. Management of prostate cancer, which often requires an interdisciplinary approach, varies greatly, depending on tumor stage, rate of tumor progression, and life expectancy.

Last month, world-renowned thought leaders assembled at the 4th Annual Interdisciplinary Prostate Cancer Congress in New York City, New York, to explore how to integrate novel therapeutics into the standard of care.

This full-day continuing medical education (CME) activity, jointly sponsored by the University of Cincinnati and ArcMesa Educators, assembled urologists, medical oncologists, and radiation oncologists from across the US and addressed hormonal therapies, imaging and staging, surgical advances, radiation therapies, and emerging multimodal therapies.*

The program cochairs were Leonard G. Gomella, MD, of Thomas Jefferson University in Philadelphia, and Daniel P. Petrylak, MD, of Columbia University College of Physicians and Surgeons in New York. Other panel members included E. David Crawford, MD, of the University of Colorado Health Sciences Center; Robert Dreicer, MD, of the Cleveland Clinic Lerner College of Medicine; Howard M. Sandler, MD, of Cedars-Sinai Medical Center in Los Angeles; and A. Oliver Sartor, MD, of Tulane Medical School in New Orleans.

Because of the diverse presentation of the disease in patients with prostate cancer, as well as the continued progress in treatment options, devising an ideal standard approach to care is an enormous challenge. But the panel agreed that the care of patients with prostate cancer often involves a thoughtful integration of modalities and a casebased approach.

*Grant support for the CME activity was partially supported by educational grants from: Centocor Ortho Biotech Services LLC; Dendreon Corporation; Endo Pharmaceuticals, Inc.; Ferring Pharmaceuticals, Inc.; and sanofi-aventis U.S.

Related Videos
Binod Dhakal, MD
Jill Corre, PharmD, PhD
Saad Z. Usmani, MD, MBA, FACP, FASCO
Ashraf Z. Badros, MBCHB
Thierry Andre, MD, professor, medical oncology, Sorbonne Université; head, Medical Oncology Department, Saint Antoine Hospital
Sanjay Popat, BSc, MBBS, FRCP, PhD, consultant medical oncologist, The Royal Marsden Hospital; professor, thoracic oncology, the Institute of Cancer Research
Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, co-leader, kidney cancer program, Dana-Farber Cancer Institute; Jerome and Nancy Kohlberg Chair, professor, medicine, Harvard Medical School
Angeles A. Secord, MD, MHSc, professor, obstetrics and gynecology, Duke Cancer Institute, discusses findings from the phase 2 PICCOLO trial (NCT05041257) investigating mirvetuximab soravtansine-gynx (Elahere) in patients with recurrent, platinum-sensitive ovarian cancer with high folate receptor alpha (FRα) expression.
Nancy U. Lin, MD, associate chief, Division of Breast Oncology, Susan F. Smith Center for Women’s Cancers, director, Metastatic Breast Cancer Program, director, Program for Patients with Breast Cancer Brain Metastases, Dana-Farber Cancer Institute; professor, medicine, Harvard Medical School
Nicolas Girard, MD, professor, respiratory medicine, Versailles Saint Quentin University; head, Curie-Montsouris Thorax Institute, chair, Medical Oncology Department, Institut Curie